What is Lifesci Capital’s Estimate for TNYA Q1 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities researchers at Lifesci Capital issued their Q1 2026 earnings per share estimates for Tenaya Therapeutics in a research report issued on Thursday, March 12th. Lifesci Capital analyst T. Pardo-Garcia forecasts that the company will earn ($0.14) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.59) EPS.

Other analysts have also recently issued research reports about the company. HC Wainwright cut their target price on Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, January 21st. Leerink Partners reiterated an “outperform” rating and set a $2.00 price objective on shares of Tenaya Therapeutics in a research report on Thursday. Chardan Capital reissued a “buy” rating and issued a $8.00 target price on shares of Tenaya Therapeutics in a report on Thursday. Finally, William Blair restated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Tenaya Therapeutics Price Performance

TNYA opened at $0.89 on Friday. The company has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $1.12. The firm has a market cap of $146.20 million, a P/E ratio of -1.44 and a beta of 3.22. Tenaya Therapeutics has a 1-year low of $0.36 and a 1-year high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Wednesday, March 11th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12).

Insider Buying and Selling at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $0.56, for a total value of $1,966,622.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 8,594,047 shares of company stock valued at $5,430,207 in the last ninety days. Insiders own 48.65% of the company’s stock.

Hedge Funds Weigh In On Tenaya Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Scientech Research LLC acquired a new stake in Tenaya Therapeutics in the third quarter worth about $27,000. Mirador Capital Partners LP raised its position in shares of Tenaya Therapeutics by 38.2% in the 3rd quarter. Mirador Capital Partners LP now owns 23,500 shares of the company’s stock valued at $38,000 after purchasing an additional 6,500 shares during the last quarter. Comerica Bank acquired a new stake in Tenaya Therapeutics in the 1st quarter worth approximately $50,000. Savant Capital LLC purchased a new stake in Tenaya Therapeutics during the 2nd quarter worth approximately $52,000. Finally, Cerity Partners LLC increased its stake in Tenaya Therapeutics by 403.5% during the 2nd quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock valued at $67,000 after purchasing an additional 88,424 shares in the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.